NCT05766319

Brief Summary

In this pilot study we will study the feasibility of providing and following ICU patients with smart technology for three months after discharge from a general ward of the Leiden University Medical Centre.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 26, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 11, 2022

Completed
4 months until next milestone

First Posted

Study publicly available on registry

March 13, 2023

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2024

Completed
Last Updated

June 14, 2024

Status Verified

June 1, 2024

Enrollment Period

1.7 years

First QC Date

November 11, 2022

Last Update Submit

June 13, 2024

Conditions

Keywords

E-healthHome monitoring devicesSmartphone-enabledHealth monitoring devicesSmart devicesUser experience

Outcome Measures

Primary Outcomes (5)

  • Feasibility of using home monitoring devices in terms of patient number

    Primary endpoint of this study is the feasibility of providing patients with the ICU-Recover Box after ICU discharge and before hospital discharge, including the collection of measurement/questionnaire data after hospital discharge. This study will be used to identify the issues when implementing such a system. Feasibility is defined as: 10 post-ICU patients, who gave informed consent and who were discharged from hospital with the ICU-Recover Box, were able to use the devices within its intended use.

    three months

  • Feasibility of using home monitoring devices in terms of data acquisition

    We were able to acquire data from the devices in the ICU-Recover Box. * Heart rate ( beats/min ) from the Withings ScanWartch * steps/day from the Withings ScanWatch * peripheral oxygen saturation (%) from the Withings ScanWatch * weight ( kg) from Withings Body * Blood pressure ( mmHg) from Withings BPM Connect

    three months

  • Feasibility of using home monitoring devices in terms of data storage

    · We were able to store the acquired data in a safe manner in the datasafe of the LUMC

    three months

  • Feasibility of using home monitoring devices in terms of data analyzability

    · We were able to analyse the acquired data (using Python).

    three to six months

  • Feasibility of using home monitoring devices

    · · \> 80 % of the persons that were discharged with an ICU-Recover Box contributed for three months to post-ICU data

    six months

Secondary Outcomes (2)

  • Acceptability of home monitoring

    three months

  • Improvements of home monitoring

    three months

Study Arms (1)

Patients receiving the ICU-recover box containing home monitoring devices

EXPERIMENTAL

Treatment of subjects on the ICU will be state of the art, conform current practice, protocols and guidelines. Patients discharged from the ICU will receive an ICU-Recover Box on one of the clinical wards of the LUMC filled with several devices after they have given informed consent. These devices are listed below and are described in further detail in section 6 of this protocol. The ICU-Recover Box contains the following devices and tools: * Withings BPM Connect * Withings Body weight scale * Withings ScanWatch, from which the following features will be used: * Measurement of SpO2 * Automatic recording of heart rate * Automatic recording of activity (step count)

Device: Withings ScanWatchDevice: Withings BPM ConnectDevice: Withings Body

Interventions

Withings ScanWatch, from which the following features will be used: * Measurement of peripheral oxygen saturation (%) * Automatic recording of heart rate (beats/min) * Automatic recording of activity (step count) (numbers/day)

Patients receiving the ICU-recover box containing home monitoring devices

Withings BPM connect, from which the following feature will be used: o Measurement of non invasive bloodpressure (mmHg)

Patients receiving the ICU-recover box containing home monitoring devices

Withings Body (Scale), from which the following feature will be used: o Measurement of body weight (kg)

Patients receiving the ICU-recover box containing home monitoring devices

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Patient has been admitted to the ICU of the LUMC for \> 48 hours.
  • Patient has received mechanical ventilation for \> 24 hours.
  • Patient masters the English or Dutch language.
  • Patient is able and capable to use smart technology at home. (i.e. Wi-Fi available, sufficient comprehension of smart technology).
  • Patient can be contacted and informed about the ICU-Recover box on one of the clinical wards of the LUMC.
  • Patient is discharged from a ward within the LUMC to home..

You may not qualify if:

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Patient is \< 18 years old.
  • Patient is pregnant.
  • Patient breastfeeds during the course of the study
  • Patient underwent cardiothoracic surgery (as they will receive the Cardiothoracic Box in another study).
  • Patient is discharged for palliative care.
  • Patient is considered an incapacitated adult.
  • Patient is unwilling to sign the informed consent form.
  • Patient is discharged to another hospital.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Leiden University Medical Center

Leiden, South Holland, 2333 ZA, Netherlands

Location

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Sesmu Arbous, MD PhD

    LUMC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DEVICE FEASIBILITY
Intervention Model
SINGLE GROUP
Model Details: 10 patients who have been admitted to the ICU, at the Leiden University Medical Centre, and have been discharged to home will be using home monitoring for 3 consecutive months after hospital discharge
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
dr.

Study Record Dates

First Submitted

November 11, 2022

First Posted

March 13, 2023

Study Start

September 26, 2022

Primary Completion

May 31, 2024

Study Completion

May 31, 2024

Last Updated

June 14, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will share

Data obtained through this study may be provided to qualified researchers with academic interest in home monitoring of ICU survivors. Data will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a data transfer agreement) are prerequisites to the sharing of data with the requesting party.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis. This is subject to individual patient consent.
Access Criteria
Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). This is also subject to individual patient consent. For more information or to submit a request, the principal investigator or a member of the research team can be contacted.

Locations